
Xeris Pharmaceuticals
@xerispharma
We’re a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.
ID: 984114817056346112
https://www.xerispharma.com 11-04-2018 17:03:51
210 Tweet
974 Followers
58 Following



Xeris Pharmaceuticals is excited to be exhibiting at ENDO 2024 in Boston. Visit us at booth 1201! Posted on behalf of our #ENDO2024 sponsor






We’ll be attending #PriMedWest2025, where we’re sharing our industry theater on 5/8 from 8:55 - 9:40 AM PT. Stop by to hear the latest about ready-to-use #Glucagon for high-risk patients with #Diabetes. Pri-Med CME #PriMed #PriMedWest #Diabetes #Hypoglycemia


Join Xeris Pharmaceuticals $XERS for an in-person and virtual analyst and investor day on June 3 at 10am ET with key opinion leaders, to discuss unmet medical needs and the outlook for Recorlev® and XP-8121. In-person RSVP: bit.ly/4d8xbvi; Virtual RSVP: bit.ly/3Z8MfmZ







We’re headed to the American Diabetes Association #ADASciSessions June 20-23! We look forward to joining the #Diabetes community, sharing our latest research, and collaborating with those shaping the future of #DiabetesCare. #Hypoglycemia #Type1Diabetes #T1D #Type2Diabetes #T2D #ADA2025


We're excited to share the first publication from our novel #Hypothyroidism treatment, XP-8121, a once-weekly subcutaneous injection. Read more on the ASCPT Alexandria website: bit.ly/4mgfcaz #InnovationInMedicine #DrugDevelopment #CompanyUpdate


Explore data that could shape the future of #DiabetesCare at American Diabetes Association #ADASciSessions. 6/22 12:30-1:30 PM CT: "Ensuring Readiness – A Case for Proactive Glucagon Prescribing for Patients at Increased Risk of Severe Hypoglycemia."


Discover simulated insights into mini-dosing #Glucagon for pediatric #DiabetesCare at American Diabetes Association #ADASciSessions. 6/22 12:30-1:30 PM CT: "Modeling to Assess Impact of Liquid, Stable Glucagon for Mini-Dosing in Pediatrics: A Simulated PK/PD Study."

